A new medication therapy management model being rolled out by CMS will test strategies to improve medication use among Medicare beneficiaries enrolled in the Part D drug program.
A new medication therapy management (MTM) model being rolled out by CMS will test strategies to improve medication use among Medicare beneficiaries enrolled in the Part D drug program.
The Part D Enhanced MTM model will assess whether providing some Medicare prescription drugs plans with additional incentives and flexibilities granted to plan design will achieve better overall goals for MTM programs.
“Through this model, we are hopeful that Part D plans will invest in medication therapy management and identify new, effective strategies to optimize medication use and improve care coordination in Medicare,” Patrick Conway, MD, MSc, CMS acting principal deputy administrator and chief medical officer, said in a statement.
Some of the goals the program is looking to achieve include: improving compliance with medication protocols, including high-cost drugs; reducing medication-related problems; increasing patients’ knowledge of their medications to better achieve goals of therapy; and improving communication among prescribers, pharmacists, caregivers, and patients.
Testing for the model will begin January 1, 2017, with a 5-year performance period and will be tested in 11 states: Arizona, Florida, Iowa, Louisiana, Minnesota, Montana, Nebraska, North Dakota, South Dakota, Virginia, and Wyoming.
During the performance period, CMS will waive current MTM program requirements for participating plans in the test regions.
The Supreme Court seems likely to reject a challenge to the abortion pill mifepristone; the FDA is inspecting far fewer pharmaceutical companies conducting clinical research; AstraZeneca has sued to block an Arkansas law that it said would unlawfully expand the 340B program to include for profit-pharmacy chains.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Covered Preventive Services at Risk: V-BID Summit Breaks Down the Braidwood v Becerra Case
March 20th 2024For more than a decade, certain high-value preventive care services have been covered at no cost to patients under the Affordable Care Act, but a current legal challenge has the coverage at risk.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Most private health insurers have yet to publish criteria for when they will cover postpartum depression drug, zuranolone; state lawmakers are increasingly opposing health care mergers that they believe do not serve the public interest; Medicaid extensions made in 2021 led to a 40% decline in postpartum lack of insurance.
Read More
President Biden will preview his plan to more than double the size of Medicare’s new drug price negotiation program in the upcoming State of the Union address; Mexicans and Central Americans were most affected by the pandemic in terms of all-cause mortality; two Alabama fertility clinics said they expect to resume in vitro fertilization (IVF) services after a bill was passed to protect doctors.
Read More